Pharmaceutical - Vanda Pharmaceuticals


Current filters:

Vanda Pharmaceuticals

Popular Filters

Positive FDA panel recommendation for Vanda’s tasimelteon

Positive FDA panel recommendation for Vanda’s tasimelteon


The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee…

HetliozNorth AmericaOphthalmicsPharmaceuticalRegulationtasimelteonVanda Pharmaceuticals

Vanda Pharma pulls EU application for schizophrenia drug candidate Fanaptum


The European Medicines Agency has been formally notified by USA-based Vanda Pharmaceuticals (Nasdaq:…

EuropeFanaptumNeurologicalPharmaceuticalRegulationVanda Pharmaceuticals

Vanda's tasimelteon meets primary endpoint in Ph III study


Shares of USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) moved 2.8% higher to $3.22 in early trading…

NeurologicalPharmaceuticalResearchtasimelteonVanda Pharmaceuticals

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions


French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Vanda gains rights to Lilly's NK-1 receptor antagonist


USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) said yesterday that it has acquired an exclusive worldwide…

Eli LillyLicensingNeurologicalPharmaceuticalVanda Pharmaceuticals

Mochida diabetes deal with Merck; Vanda links with Megapharm


Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen,…

BiotechnologyDiabetesFanaptLicensingMegapharmMerck & CoMochida PharmaceuticalNeurologicalPharmaceuticalVanda Pharmaceuticals

Back to top